Bedrijfsoverzicht
Myriad Genetics, Inc. is a prominent entity within the healthcare sector, specifically operating in the diagnostics and research industry, where it focuses on the development of molecular tests for oncology, women's health, and pharmacogenomics. The company's core offerings include the MyRisk Hereditary Cancer test, which utilizes DNA sequencing to identify hereditary cancers, alongside a comprehensive suite of diagnostic solutions designed to support precision medicine initiatives. As of the latest available data, the company maintains a market capitalization of $406.76M and employs a workforce of 2,700 individuals dedicated to advancing molecular diagnostic capabilities. With annual revenue reaching $557.00M, these financial figures indicate that Myriad Genetics holds a significant position within its niche, though the market cap relative to revenue suggests a valuation structure that prioritizes future diagnostic potential over current profitability metrics.
Financiële gezondheid
The company reported a revenue of $557.00M for the trailing twelve months, yet this top-line performance is offset by a net income of -$230,000,000 and an EBITDA of -$111,900,000, revealing a substantial gap between gross sales and bottom-line earnings that points to high operational expenses or significant one-time costs impacting the bottom line. This negative net income contrasts with a cash position of $150.70M and zero recorded debt, creating a scenario where the company holds ample liquidity despite reporting losses on an accrual basis. The free cash flow stands at -$46,062,500, which indicates that the company is currently consuming cash to fund its operations and growth initiatives rather than generating surplus capital for distribution or aggressive buybacks. Margin analysis further highlights structural challenges, with a gross margin of 68.1% suggesting strong pricing power or product mix efficiency, but an operating margin of -21.4% and a profit margin of -41.3% demonstrating that overhead costs and non-operating items are severely eroding profitability. In terms of leverage, the company possesses no debt against its $150.70M cash reserve, resulting in a debt-to-equity ratio listed as 32.84, a figure that must be interpreted alongside the negative equity base implied by the losses. The current ratio of 2.67 confirms a robust short-term liquidity position, providing a comfortable buffer against immediate obligations. Furthermore, the return on equity is -23.5% and the return on assets is -7.6%, metrics that collectively reveal that management is currently generating negative returns on the capital employed, signaling a period of investment or restructuring rather than value creation.
Waarderingsbeoordeling
Valuation metrics for Myriad Genetics present a complex picture, with a trailing P/E ratio marked as N/A due to the negative net income, while the forward P/E is projected at 25.91, implying that the market expects earnings to turn positive or improve significantly in the coming fiscal periods. The price-to-book ratio sits at 1.11, indicating that the stock trades slightly above its book value, a premium that investors may attribute to the company's intangible assets and proprietary diagnostic technologies rather than tangible balance sheet strength. Alternative valuation measures provide additional context, with a price-to-sales ratio of 0.73 and an EV/EBITDA of -2.29, suggesting that the market is pricing the company based on revenue multiples rather than earnings multiples due to the current lack of profitability. The stock's trading range over the past year is defined by a 52-week high of $8.59 and a low of $3.76, placing the current share price within a volatile band that reflects the uncertainty surrounding its path to profitability. The beta value of 1.64 highlights that the stock is significantly more volatile than the broader market, moving with greater amplitude than the average equity and reflecting the high-risk profile associated with biotech and diagnostic firms awaiting clinical or commercial milestones.
Growth & Income
Growth dynamics for the company are characterized by a revenue contraction of -20.8% year-over-year, while earnings growth is not applicable given the negative net income, indicating that the decline in sales has directly translated into deeper losses rather than a decoupling of revenue and earnings trends. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings and cash flow are being retained and reinvested into research, development, and operational scaling rather than being distributed to shareholders. This reinvestment strategy is typical for firms in the diagnostics and research industry that must prioritize capital expenditure to maintain competitive advantages in molecular testing. Overall, the growth and income profile is defined by a period of negative revenue expansion and a complete absence of income distribution, positioning the company as a capital-intensive player focused on long-term market positioning rather than short-term shareholder returns.